Sermorelin
Also known as: GHRH 1-29, GRF 1-29
Sermorelin is a bioidentical synthetic version of growth hormone releasing hormone (GHRH) consisting of the first 29 amino acids of the full 44-amino acid GHRH molecule. It is FDA-approved for diagnostic testing of GH secretion but is widely used off-label for anti-aging and growth hormone optimization. Unlike direct HGH replacement, sermorelin stimulates the body's own production of growth hormone.
Bioidentical analog of growth hormone releasing hormone (GHRH) that stimulates natural GH production
| Parameter | Detail |
|---|---|
| Administration | Subcutaneous injection |
| Typical Dose | 200-500mcg daily before bed |
| Frequency | Daily |
Common Side Effects
Serious Side Effects
- Active cancer
- Pituitary tumor
- Pregnancy
- Children with closed growth plates
Evidence Quality
Clinical Trial Phase
Approved (post-market)
| Peptide | Monthly Cost | FDA Status |
|---|---|---|
| Sermorelin | $150 - $350/mo | FDA Approved |
| MK-677 | $50 - $100/mo | Phase 2 |
| CJC-1295 | $35 - $70/mo | Not submitted |
| Ipamorelin | $35 - $70/mo | Not submitted |
| GHRP-6 | $35 - $70/mo | Not submitted |
Medical Disclaimer
The information provided on this page is for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or modifying any peptide therapy or medication. PeptideVS does not endorse, recommend, or promote the use of any specific peptide for medical treatment. Clinical data cited may be from ongoing trials and is subject to change. Individual results may vary.